Details of the Drug

General Information of Drug (ID: DMHJV0X)

Drug Name
Pertuzumab
Synonyms Pertuzumab (genetical recombination); Pertuzumab (USAN/INN); Pertuzumab (genetical recombination) (JAN); Pertuzumab (ERBB2 mAb inhibitor)
Indication
Disease Entry ICD 11 Status REF
Adrenal gland neoplasm N.A. Approved [1]
Breast cancer 2C60-2C65 Approved [2]
Neuroblastoma 2D11.2 Investigative [1]
Affected Organisms
Humans and other mammals
ATC Code
L01FD02: Pertuzumab
L01FD: HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
L01F: MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Monoclonal antibody
Sequence
>light chain
DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPS
RFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
>heavy chain
EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGGSIY
NQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSSA
STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGP
SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS
TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEM
TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPG
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 4 days [3]
Clearance
The clearance of drug is 0.24 L/day [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 18 days [4]
Vd
The volume of distribution (Vd) of drug is 3.53-7.5 L [3]
Cross-matching ID
UNII
K16AIQ8CTM
DrugBank ID
DB06366
TTD ID
D0CI4E
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Erbb2 tyrosine kinase receptor (HER2) TT6EO5L ERBB2_HUMAN Inhibitor [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Adrenal gland neoplasm
ICD Disease Classification
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Erbb2 tyrosine kinase receptor (HER2) DTT ERBB2 2.78E-03 0.59 4.11
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5046).
3 Health Canada Product Monograph: Perjeta (pertuzumab) for intravenous injection
4 FDA Approved Drug Products: Perjeta (pertuzumab) for intravenous injection
5 Clinical pipeline report, company report or official report of Roche (2009).